Sam Keeping

Cost–effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK

Yiling Jiang, Aline Gauthier, Sam Keeping et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2014 · 31 citations

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis

Gerasimos Konidaris, E. Paul, Andreas Kuznik et al. · Value in Health · 2021 · 31 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Risk Communication and Crisis Communication in Infectious Disease Outbreaks in Germany: What Is Being Done, and What Needs to be Done

Petra Dickmann, Nadine Biedenkopf, Sam Keeping et al. · Disaster Medicine and Public Health Preparedness · 2014 · 15 citations

Management, Emergency Preparedness, Risk Management +12

Clinical impact of rapid molecular diagnostic tests in patients presenting with viral respiratory symptoms: A systematic literature review

Ali Mojebi, Ping Wu, Sam Keeping et al. · PLoS ONE · 2024 · 12 citations · Full text

Medicine, Clinical Sciences, Infectious Diseases +17

A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK

Yiling Jiang, Aline Gauthier, Sam Keeping et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2014 · 10 citations

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17